Eli Lilly agrees to pay $57 a share for Morphic, a 79% premium to the stock’s closing price of $31.84 on Friday.
Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the ...
Eli Lilly & Co. has announced the acquisition of Morphic Holding Inc., a US-based biotech company specializing in treatments ...
Eli Lilly says it will acquire a Waltham-based drug company that's working on a treatment for inflammatory bowel disease.
It was a mating dance that lasted more than three years. At the end, Eli Lilly and Co. wound up buying a Massachusetts-based ...
Eli Lilly agreed to buy Waltham-based gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline.
Eli Lilly will acquire Morphic Holding for $3.2 billion, the companies said on Monday, giving the U.S. drugmaker access to an ...
Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in ...
The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.
Eli Lilly said it would buy Morphic for roughly $3.2 billion or $57 per share, a nearly 80% premium to Friday's closing price. Morphic is developing a treatment for inflammatory bowel disease.
Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for inflammatory bowel disease.
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...